Data Abstraction Form:

Investigation of Mucormycosis Disease among Bone Marrow Transplant Patients

Initials:	
Case #:	
Medical Record #:	
Date of Birth:	
Reviewers Initials:	
Review Date:	

Case of Mucormycosis Infection of Interest

Bone marrow transplant patients with stays in unit 41 and 42 with any presentation of a mucormycosal infection excluding gastrointestinal

WITH

Histopathological or cytopathological examination showing hyphae from needle aspiration or biopsy specimen with evidence of associated tissue damage (either microscopically or as an infiltrate or lesion by imaging)

OR

Positive culture result for a sample obtained by sterile procedure from normally sterile and clinically or radiologically abnormal site consistent with mucormycosal infection.

Matched Controls

Bone marrow transplant patients (Preferred) with stays in unit 41 and 42:

- a date of birth is within five years of the matched mucormycosis case's birthday
- with matched hematologic malignancy (See section II)

Other major risk factors we will assess for and enough controls present, we can consider matching for diabetes status, diabetic ketoacidosis, blood iron overload condition, chronic high-dose corticosteroids use. If necessary we can also expand the control group to hematopoietic stem cell transplant from unit 41, or from unit 41 and 42.

Public reporting burden of this collection of information is estimated to average 90 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

Case-Case Abstraction Form

History of stem cell transplant

Section I: Demographic and Admission Data 1. Age at diagnosis (years): ____ 2. Gender: _____(0= Male, 1= Female) 3. Race (Select all that apply): (0=white/Caucasian, 1=black/African-American, 2=Asian, 3=American Indian/Alaskan, 4=Hawaiian/Pacific Islander, 5=not known) Ethnicity: _____(0=not Hispanic, 1=Hispanic, 2=not known) County: ____ State: _____ Phone #: Date of admission (mm/dd/yy): Admit diagnosis: ___ Section II: Underlying Medical Conditions and Risk Factors (at time of admission or before onsets, check all that apply) 9. General Medical Conditions: None Bone Marrow Transplant Other hematopoietic stem cell transplant Diabetes [not Diabetic Ketoacidosis (DKA)] Last Hemoglobin A1C level _____ Diabetic Ketoacidosis (DKA) during stay on unit Hemochromatosis Thalassemia Transfusion-induced iron overload in the 14 days before or during say on unit ___ Iron overload for any other reason and/or iron chelation therapy within 14 days prior to exposure to the unit (Desferrioxamine therapy) None 10. Immunocompromised State: Solid organ transplant (ever) renal liver lung heart other (specify) If transplant recipient, date of most recent transplant (mm/dd/yy): ____/___/ Solid tumor malignancy (specify type): _____ If history of solid tumor, on or had been on chemotx in the 14 days before culture? Yes No Unknown

Neutropenia (< 500 neutrophils per mm³) within 14 days prior to onset (or admission?)

Total number of neutropenic days within 14 day period:ororOrOn
Systemic corticosteroids at avg dose ≥0.3 mg/kg/day prednisone (or equivalent) for > 3 weeks
Chronic Granulomatous Disease
Other(specify)
Hematologic malignancy
Leukemia
Acute myeloid leukemia (AML) (e.g. M0-M7)
Chronic myeloid leukemia (CML) (e.g. Chronic phase, Accelerated phase, Blast crisis)
Acute lymphocytic leukemia (ALL) (e.g. L1-L3)
Chronic lymphocytic leukemia (CLL) (e.g. B cell origin, T cell origin, Adult T cell leukemia, Sezary
syndrome, Unclassified)
Hodgkin's disease (e.g. Lymphocyte predominant, Lymphocyte rich, Nodular sclerosis, Hairy cell leukemia,
Mixed cellularity, Lymphocyte depleted, Large, granular lymphocyte leukemia)
Non-Hodgkin's lymphoma (e.g. B cell origin, T cell origin)
Aplastic anemia
Multiple myeloma
Myelodysplastic syndrome (e.g. RA, RARS, RAEB-1, RAEB-2, RCMD, RCMD/RS, 5q syndrome, CMML)
☐ Sickle cell anemia
Other
If history of heme malignancy, on or had been on chemotx in the 14 days before culture?
Yes No Unknown
Graft-versus-host disease:
Acute; if yes, record grade (I-IV)
☐ Chronic; if yes, check one: ☐ limited ☐ extensive ☐ unknown
None
Unknown

Section III: Location

_		_	thin 30 days prior to the cur	rent admission?
<u>`</u>	cations, including those relow, with most recent he	· · · · · · · · · · · · · · · · · · ·	No Unknown	
Facility Name	Admission Dates	Ward/Bed	First date at location	Last date at location
	(mm/dd/yy)-	(complete for each		
	(mm/dd/yy)	location)		
			Unk	Unk
			Unk	
				Unk
Other acute care Rehabilitation Other (specify): Unknown	ng current admission:			
Ward/Room	First date at location		Last date at location (or	r Unk)
		Unk		Unk

Culture Date	Specimen Site/Type	Organism
(mm/dd/yy)	(blood, sputum, pleural fl	luid,
	CSF, etc)	
5. Did patient have a pos	itive Mucor pathology finding?	Yes No Unknown
If yes, please complete	e table:	
Date (mm/dd/yy)	Anatomical site	Organism/Description of Fungal Elements
6. If patient had a head (CT, please list date:	
Cavernous sinus th		
Changes to the orb		
Semiacute right from		
Diffuse sinusitis		
Describe other finding	s:	
7. If patient had a head N	ARL please list date:	
Cavernous sinus th		
Changes to the orb		
Semiacute right from		
Diffuse sinusitis	intal look infarct	
Describe other finding	99.	
	a history of positive cultures for N	Mucor? Yes No Unknown
If yes, date of previous]
ii yes, date of previous	s culture.	J
on V: Medications/Proce	edures	
19. Has patient received in	nmunosuppressive medications (i	including chemotherapy) within 30 days of the index culture
date? Yes N	No Unknown	
If yes, please list:	1)	
	2)	
	3)	
	4)	
	,	

Aut's and I		wn Track been of	Day (last)
Antifungal drug	Given?	Total days of therapy in 30- day period	Date of last dose prior to first culture (mm/dd/yy)
Amphotericin B	Yes		
(Polyene Antifungal)	No Unknown		Unk
Fungizone,	Chianown		
(Lipid-based Polyene Antifungal)			
Amphotec Abelcet			
AmBisome Amphocil,			
☐ ABLC ☐ ABCD			
Anidulafungin (Eraxis) (an	Yes		
Echinocandin)	No Unknown		Unk
Caspofungin (Cancidas) (an	Yes		
Echinocandin)	No Unknown		Unk
Fluconazole (Diflucan) (an Azole)	Yes No Unknown		Unk
Flucytosine (5FC) (a Nucleoside	Yes		
Analog Antifungal)	No Unknown		Unk
Micafungin (Mycamine) (an	Yes		
Echinocandin)	No Unknown		Unk
Posaconazole (Noxafil) (an Azole)	Yes No Unknown		Unk
Itraconazole (Sporanox) (an Azole)	Yes		
	No Unknown		Unk
Voriconazole (Vfend) (a Triazole)	Yes		
	No		Unk
	Unknown		
1. Was the patient intubated? Yes	No Unk	nown	
If yes, complete the following questic	ons:		
a. Where was the patient intub	ated? (ER, floor, IC	CU, field):	
_	ral Nasal		
c. List dates of intubation:			
d. Did index culture date occur			After

	a.	If yes,	date of trach	eostomy?/			
	b.	If yes,	did index cul	ture date occur prior	to or after tr	acheostomy? Prior	After
23.	Did the Yes e.	If yes,		own		30 days before the index cul	
			CPAP/BIPAP	Other		None	Unknown
				SVN or MDI, fill in	the table belo		
				Drug	M	ode of Administration (SV	/N or MDI)
24.	Did pat	ient hav	e anv procedi	ıres within 30 days p	orior to the in	dex culture date?	
	Yes						
	If yes, p	olease cl	heck all that a	pply:			
		Th	oracentesis			Date: //////	
		Bro	onchoscopy			Date:	
						Date://	
						Date://_	
		Th	oracotomy (C	Chest tube insertion)		Date:///	
		En	doscopy			Date://	
		Tra	ansesophagea	l echocardiogram		Date:	
		Su	rgery (1)			Date:	
						OR #:	
			(2)			Date:	
						OR #:	
		Per	rcutaneous/in	terventional radiolog	y procedure:		
			fy) Date:		(specify)	Date:	
		0.			_(specify)	///	

Sec	tion VI: Symptoms				
25.	Was the onset of symptoms more chron	nic, over the course	e of several weeks?	Yes No Unknown	
26.	Manifested as an acute sinus infection?	Yes No	Unknown		
27.	Nasal congestion? Yes No	Unknown			
28.	Fever? Yes No Unknown	n			
29.	Headache? Yes No Unkı	nown			
30.	Facial pain? Yes No Unl	known			
31.	Tinnitus? Yes No Unkno	own			
32.	Reddish and swollen skin over nose an	d sinuses? Yes	No Unkno	own	
33.	Periorbital edema and erythema (Redd	ish and swollen ski	n around the eye)?	Yes No Unknown	
34.	Ptosis of the eyelid? Yes No	Unknown			
35.	Visual problems? Yes No	Unknown			
36.	Edema and hypertrophy of the nasal tu	rbinates? Yes	No Unknow	vn	
37.	Edema and hypertrophy of the posterio	or pharynx? 🗌 Yes	No Unkn	own	
38.	Altered mental status? Yes No	Unknown			
39.	Blindness of the eye? Yes No	Unknown			
40.	Dilated pupil? Yes No U	Jnknown			
41.	Nonreactive pupil? Yes No	Unknown			
42.	2. Cavernous sinus thrombosis? Yes Unknown				
43.	3. Evidence of spread to the brain? Yes Unknown				
44.	44. Spread to the orbits? Yes No Unknown				
	tion VII: Treatment Did the patient undergo debridment?	Yes No	Unknown		
46.	46. Myringotomy with insertion of a tympanostomy?				
47.	47. Hyperbaric oxygen therapy (HBO)?				
48.	48. Did the patient undergo surgery for treatment (not diagnosis) of rhinocerebral mucormycosis?				
49.	49. Yes No Unknown				
50.	50. If yes, what was the name of the procedure? (e.g. Frontal lobectomy, Ethmoidectomy, Maxillary sinus antrostomy, Frontal sinusotomy, Sphenoidectomy)				
51.	Was the patient treated with an antifun	gal after the infecti	on was diagnosed?	Yes No Unknown	
	If yes, complete table:				
	Antifungal drug	Given?	Total days of therapy in 30- day period	Date of last dose prior to first culture (mm/dd/yy)	
Aı	mphotericin B	Yes	day period		
	(Polyene Antifungal) No Unknown Unknown			Unk	
	Fungizone,				
	(Lipid-based Polyene Antifungal)				

AmBisome Amphocil,	Anidalfungin (Eraxis) (an	Amphotec Abelcet					
Arridulafungin (Eraxis) (an	Anidulafungin (Eraxis) (an	AmBisome Amphocil,					
Arridulafungin (Eraxis) (an	Anidulafungin (Eraxis) (an						
Echinocandin)	Echinocandin)	☐ ABLC ☐ ABCD					
Lechinocandin Unknown Unknown	Caspofungin (Cancidas) (an	Anidulafungin (Eraxis) (an					
Echinocandin)	Echinocandin)	Echinocandin)		Unk			
Echinocandin)	Echinocandin)	Caspofungin (Cancidas) (an					
No	No	Echinocandin)		Unk			
Flucytosine (SFC) (a Nucleoside	Flucytosine (5FC) (a Nucleoside	Fluconazole (Diflucan) (an Azole)					
Flucytosine (5FC) (a Nucleoside	Flucytosine (5FC) (a Nucleoside			Unk			
Micafungin (Mycamine) (an	Allang Antitungal) Unknown	Flucytosine (5FC) (a Nucleoside	Yes				
Micafungin (Mycamine) (an Echinocandin)	Micafungin (Mycamine) (an Echinocandin)	Analog Antifungal)		Unk			
Centinocandin	Chinocandin	Micafungin (Mycamine) (an	Yes				
Posaconazole (Noxafil) (an Azole)	Posaconazole (Noxafil) (an Azole)	Echinocandin)		Unk			
Itraconazole (Sporanox) (an Azole) Ves No Unknown Unk Voriconazole (Vfend) (a Triazole) Yes No Unknown Unk Voriconazole (Vfend) (a Triazole) Yes No Unknown Unk 52. Renal indices monitored during therapy? Yes No Unknown 53. Nephrotoxicity levels during treatment 54. Iron chelator therapy? Yes No Unknown 55. Deferasirox? Yes No Unknown 56. Deferiprone? Yes No Unknown 57. Was infected sinus tissue or sinus tissue destruction visibly observed? Yes No Unknown 58. Significant devitalized mucous membranes? Yes No Unknown 59. Significant devitalized mucous membranes? Yes No Unknown 60. Necrotic lesions in the: f. Nasal mucosa? Yes No Unknown g. Turbinates? Yes No Unknown h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown	Itraconazole (Sporanox) (an Azole)	Posaconazole (Noxafil) (an Azole)	Yes				
Itraconazole (Sporanox) (an Azole) Yes No Unknown Voriconazole (Vfend) (a Triazole) Yes No Unknown Unk Yes No Unknown Unk Yes No Unknown Unk 1. Voriconazole (Vfend) (a Triazole) Yes No Unknown Section VII: Outcomes 7. Was infected sinus tissue or sinus tissue destruction visibly observed? Yes No Unknown Section VII: Outcomes No Unknown Section VII: Outcomes No Unknown Unknown Section VII: Outcomes No Unknown Unknown Section VII: Outcomes To Was infected sinus tissue or sinus tissue destruction visibly observed? Yes No Unknown Unknown No Unknown Section VII: Outcomes To Was infected sinus tissue or sinus tissue destruction visibly observed? Yes No Unknown Unknown Unknown Section VII: Outcomes To Was infected sinus tissue or sinus tissue destruction visibly observed? Yes No Unknown	Itraconazole (Sporanox) (an Azole)			Unk			
Unknown Voriconazole (Vfend) (a Triazole) Ves No Unknown Unk 52. Renal indices monitored during therapy?	Voriconazole (Vfend) (a Triazole) Ves	Itraconazole (Sporanox) (an Azole)	Yes				
Voriconazole (Vfend) (a Triazole) Yes No Unknown Unk 100 Wes No Unknown Unknown 100 Wes No Unknown 100 Wes No Unknown Unknown Wes No Unknown Unknown Wes No Unknown Unknown Unknown Wes No Unknown Wes No Unknown Unknown Unknown Wes No Unknown	Voriconazole (Vfend) (a Triazole) Yes No Unknown Unk S2. Renal indices monitored during therapy? Yes No Unknown S3. Nephrotoxicity levels during treatment S4. Iron chelator therapy? Yes No Unknown S5. Deferasirox? Yes No Unknown S6. Deferiprone? Yes No Unknown Section VII: Outcomes S7. Was infected sinus tissue or sinus tissue destruction visibly observed? Yes No Unknown S8. Significant devitalized mucous membranes? Yes No Unknown S9. Significant devitalized mucous membranes? Yes No Unknown S9. Significant devitalized mucous membranes? Yes No Unknown S9. Turbinates? Yes No Unknown G0. Necrotic lesions in the: f. Nasal mucosa? Yes No Unknown h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown G2. Invasion of the surrounding vasculature? Yes No Unknown			Unk			
Unknown Unkn	Unknown	Voriconazole (Vfend) (a Triazole)	Yes				
52. Renal indices monitored during therapy?	52. Renal indices monitored during therapy? Yes No Unknown 53. Nephrotoxicity levels during treatment			Unk			
53. Nephrotoxicity levels during treatment 54. Iron chelator therapy?	53. Nephrotoxicity levels during treatment 54. Iron chelator therapy?						
54. Iron chelator therapy?	54. Iron chelator therapy?	52. Renal indices monitored during therap	y? Yes No Unknown				
55. Deferasirox?	55. Deferasirox?	53. Nephrotoxicity levels during treatmen					
Section VII: Outcomes 57. Was infected sinus tissue or sinus tissue destruction visibly observed?	Section VII: Outcomes 57. Was infected sinus tissue or sinus tissue destruction visibly observed?	54. Iron chelator therapy? Yes Yes	o Unknown				
Section VII: Outcomes 57. Was infected sinus tissue or sinus tissue destruction visibly observed? Yes No Unknown 58. Significant devitalized mucous membranes? Yes No Unknown 59. Significant devitalized mucous membranes? Yes No Unknown 60. Necrotic lesions in the: f. Nasal mucosa? Yes No Unknown g. Turbinates? Yes No Unknown h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown	Section VII: Outcomes 57. Was infected sinus tissue or sinus tissue destruction visibly observed?	55. Deferasirox? Yes No U	55. Deferasirox? Yes No Unknown				
57. Was infected sinus tissue or sinus tissue destruction visibly observed?	57. Was infected sinus tissue or sinus tissue destruction visibly observed?	56. Deferiprone? Yes No Unknown					
57. Was infected sinus tissue or sinus tissue destruction visibly observed?	57. Was infected sinus tissue or sinus tissue destruction visibly observed?						
58. Significant devitalized mucous membranes?	58. Significant devitalized mucous membranes?						
59. Significant devitalized mucous membranes?	59. Significant devitalized mucous membranes? Yes No Unknown 60. Necrotic lesions in the: f. Nasal mucosa? Yes No Unknown g. Turbinates? Yes No Unknown h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown			es			
60. Necrotic lesions in the: f. Nasal mucosa? Yes No Unknown g. Turbinates? Yes No Unknown h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown	60. Necrotic lesions in the: f. Nasal mucosa? Yes No Unknown g. Turbinates? Yes No Unknown h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown						
f. Nasal mucosa? Yes No Unknown g. Turbinates? Yes No Unknown h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown	f. Nasal mucosa? Yes No Unknown g. Turbinates? Yes No Unknown h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown		anes? Yes No Unknown				
g. Turbinates? Yes No Unknown h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown	g. Turbinates? Yes No Unknown h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown						
h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown	h. Hard palate? Yes No Unknown 61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown						
61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown	61. Extension of the disease into the: Maxillary sinus? Yes No Unknown 62. Invasion of the surrounding vasculature? Yes No Unknown						
Maxillary sinus?	Maxillary sinus?		No Unknown				
62. Invasion of the surrounding vasculature? Yes No Unknown	62. Invasion of the surrounding vasculature?		No. II-lares				
62 Caread into the cribriform plate or the orbital areas	os. Spread into the cribritorin plate of the orbital apex? Yes NO Unknown						
os. Spread into the criothorn plate of the ofbital apex? Yes INO Unknown		os. Spread into the cribriform plate or the	oronar apex : res NO Ur	IKIIUWII			

64.	Did the patient require enucleation? Yes No Unknown
65.	Occlusion of the carotid artery, causing an internal carotid artery pseudoaneurysm?
	Yes No Unknown
66.	Infarction and necrosis of tissues in other structures?
	Other structures involved?
67.	Was patient diagnosed with rhinocerebral mucormycosis in the medical record?
	Yes Unknown Not applicable
68.	Date of discharge (mm/dd/yy):///
69.	Status at discharge:
	Alive Deceased Unknown
70.	If deceased, date of death:
71.	If patient is deceased, is death certificate available?
	Yes Unknown Not applicable
72.	If yes, is invasive fungal infection (IFI) listed as cause of death?
	Yes Unknown Not applicable
	If yes, is IFI listed as primary or secondary cause of death? Primary Secondary
73.	If patient is deceased, was an autopsy performed?
	Yes Unknown Not applicable
74.	If yes, was evidence of invasive fungal infection (IFI) present?
	Yes No Unknown Not applicable